Search companies on Owler
Advanced Search
Latest news
Newsfeed
My followed companies
Followed Companies

bluebird bio's Competitors, Revenue, Number of Employees, Funding and Acquisitions

bluebird focuses on developing transformative gene therapies for severe genetic diseases and cancer.

bluebird bio's headq... Read more

Based on data from bluebird bio's latest SEC filings

Annual Revenue

Based on data from bluebird bio's latest SEC filings

Employees

Nick Leschly's photo - President & CEO of bluebird bio

President & CEO

Nick Leschly

CEO Approval Rating

79/100

OVERVIEW

Founded:

1992

Headquarters:

Cambridge, Massachusetts
Greater Boston

Status:

PublicNASDAQBLUE

Industry Sector:

Biotechnology

SIC Code:

2836NAICS listing »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Spark Therapeutics a competitor of bluebird bio?

I don't know

Trending News for bluebird bio and bluebird bio's Competitors

June 4, 2020

Reuters

UPDATE 1-Roche test receives FDA emergency use approval for COVID-19 patients

Drugmaker Roche has received emergency use authorisation from the U.S. Food and Drug Administration f... See more »

Today 10:46 AM

Reuters

Lonza picks Roche exec as CEO, ending year of turmoil at the top

Lonza Group on Friday named a veteran Roche manager to become its new chief executive, as the Swiss c... See more »

June 3, 2020

FinanzNachrichten

AGEN, AGE To Battle Coronavirus, BCLI Awaits ALS Trial Data, FDA Delays Decision On NVS' Drug

BASEL (dpa-AFX) - Today's Daily Dose brings you news about Agenus' foray into COVID-19 drug developme... See more »

Competitive Analysis

TOP COMPETITORS OR ALTERNATIVES

Sangamo is the biggest rival of bluebird bio. Sangamo was founded in 1995, and its headquarters is in Brisbane, California. Sangamo operates in the Biotechnology industry. Sangamo has 410 fewer employees than bluebird bio.

Ember Therapeutics has been one of bluebird bio's top competitors. Ember Therapeutics is a Public company that was founded in New York, New York in 2011. Ember Therapeutics competes in the Health Care Services industry. Ember Therapeutics has 761 fewer employees vs. bluebird bio.

Recombinetics is bluebird bio's #3 rival. Recombinetics was founded in 2008 in Saint Paul, Minnesota. Recombinetics is in the Biotechnology industry. Recombinetics generates $39.7M less revenue than bluebird bio.

RANK

COMPANY

LEADERSHIP

CEO SCORE

EMPLOYEES

TOTAL FUNDING

REVENUE

Nick Leschly

President & CEO

- -
764
$275.9M
$44.7M
1

Sandy Macrae

President & CEO

77/100
302
$71.5M
$107.4M
2

CEO

- -
3
$1M
$6.4M
3

Mark Platt

CEO

82/100
40
$73.3M
$5M
4

Jeffrey D Marrazzo

Co-Founder & CEO

90/100
368
$377.8M
$69.9M
5

Bahija Jallal

CEO

88/100
461
$490M
$30M
6

Michael P. Bailey

President & CEO

80/100
17
$319.4M
$28M
7

Daniel G. Welch

President & CEO

66/100
269
$125M
$111.4M
8

Severin Schwan

CEO

77/100
3,700
- -
$857.3M
9

Christi L. Shaw

CEO

83/100
447
$225.2M
$32.1M
10

Jeffrey Jonas

CEO

85/100
637
$193M
$8.7M
The top 10 competitors in bluebird bio's competitive set are Sangamo, Ember Therapeutics, Recombinetics, Spark Therapeutics, Immunocore, AVEO Oncology, InterMune, Roche, Kite and Sage Therapeutics. Together they have raised over 1.9B between their estimated 102.3K employees. bluebird bio has 764 employees and is ranked 2nd among it's top 10 competitors. The top 10 competitors average 637.

Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$44.7M

bluebird bio's revenue is the ranked 5th among it's top 10 competitors. The top 10 competitors average 118.3M. Over the last four quarters, bluebird bio's revenue has grown by 16.8%. Specifically, in Q4 2019's revenue was $22.5M; in Q3 2019, it was $8.9M; in Q2 2019, it was $13.3M; in Q4 2018, bluebird bio's revenue was $19.2M.

Acquisitions

No recent acquisitions found related to bluebird bio

bluebird bio Funding History

Since bluebird bio was founded in 1992, it has participated in 6 rounds of funding. In total bluebird bio has raised $275.9M. bluebird bio's last funding round was on Jun 2013 for a total of $116.1M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

IPO
Jun 2013
$116.1M
-
Grant
Oct 2012
$9.3M
Series D
Jul 2012
$60M
Series C
Apr 2011
$30M
Series B
Mar 2010
$37.5M

Total Funding: $275.9M

Since bluebird bio was founded in 1992, it has participated in 6 rounds of funding. In total bluebird bio has raised $275.9M. bluebird bio's last funding round was on Jun 2013 for a total of $116.1M

Investments

No recent investments found related to bluebird bio

bluebird bio News

May 18, 2020Contract Pharma

bluebird bio Amends CAR-T Collaboration Agreement

Bristol Myers Squibb assumes responsibility for vector manufacturing in ex-U.S. territories... See more »
May 14, 2020TheStreet

Bristol-Myers to Resubmit Myeloma-Drug Bid to FDA - Here's the Trade

Click to view a price quote on BMY.... See more »
May 11, 2020Reuters

UPDATE 1-Bristol Myers to pay bluebird $200 mln for future royalties on cancer therapies

Bluebird bio Inc said on Monday Bristol Myers Squibb Co would give it a one-time payment of $200 mill... See more »
May 11, 2020Contract Pharma

HCATS, Apceth Expand Manufacturing Pact with Bluebird Bio

Enter long-term development and manufacturing services agreements for clinical and commercial supply ... See more »
May 11, 2020MarketScreener

Amends Promotion/Development Agreement With Bristol Myers

(marketscreener.com) By Chris Wack Bluebird bio Inc. said Monday it has amended its existing co-promo... See more »
May 11, 2020MarketScreener

Provides Operational and Business Update and Reports First Quarter 2020 Financial Results

(marketscreener.com) - Alignment with FDA on an accelerated regulatory path for LentiGlobin for sickl... See more »
April 29, 2020BioSpace

bluebird bio Announces First Quarter 2020 Earnings Conference Call and May Investor Event

bluebird bio, Inc. (NASDAQ: BLUE) today announced it will hold a conference call to discuss first qua... See more »

bluebird bio Press Releases

January 31, 2018ForImmediateRelease

CAR-T Cell Therapy For Multiple Myeloma Disease and Pipeline Summary

Travel & Tourism Industry release: This report consists of a comprehensive executive presentation det... See more »
September 20, 2017Business Wire

Global CAR-T Therapy Overview 2017 - Research and Markets

DUBLIN--(BUSINESS WIRE)--The "CAR-T Therapy Overview" drug pipelines has been added to Research and M... See more »
August 2, 2017STREETINSIDER

bluebird bio Reports Second Quarter 2017 Financial Results and Recent Operational Progress

bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially trans... See more »
June 1, 2017Business Wire

bluebird bio to Present at Two Investor Conferences in June

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company commit... See more »
January 4, 2017Blackbird

bluebird bio to Present at the 35th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass.-(BUSINESS WIRE)-bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committe... See more »
December 5, 2016NewsMaker

Burkitt Lymphoma H2 2016 Therapeutics Review Featuring Drug Profiles, Latest Dormant Projects, Product Development, News & Press Releases

Burkitt Lymphoma Pipeline Review, H2 2016, latest research study provides in depth analysis on Cellul... See more »
November 13, 2016Business Wire

bluebird bio to Present New Data from Novel Anti-BCMA CAR T Cell Therapy bb2121 at EORTC-NCI-AACR Molecular Targets and Cancer Therapies Symposium

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company commit... See more »

bluebird bio Videos

August 7, 2019bluebird bio Youtube Channel

"bluebirds rise up" on YOUTUBE

See more »
July 31, 2019bluebird bio Youtube Channel

"Deb & Allan: bluebird day" on YOUTUBE

See more »
July 8, 2019bluebird bio Youtube Channel

"How bluebird bio got it's name" on YOUTUBE

See more »
November 30, 2018bluebird Youtube Channel

"Why I Fly Kristin Wolff" on YOUTUBE

See more »
November 2, 2018bluebird bio Youtube Channel

"Why I Fly - Mark Omobono" on YOUTUBE

See more »
August 22, 2018bluebird bio Youtube Channel

"Why I Fly - Lesley & Bethany" on YOUTUBE

See more »
December 21, 2017bluebird bio Youtube Channel

"Immunotherapy Carolers" on YOUTUBE

See more »

Social Statistics

Headquarters

60 Binney Street

Cambridge, Massachusetts02142

1-339-499-9300

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

bluebird focuses on developing transformative gene therapies for severe genetic diseases and cancer. bluebird bio was founded in 1992. bluebird bio's headquarters is located in Cambridge, Massachusetts, USA 02142. It has raised 275.9M in 6 rounds. The...

CEO

bluebird bio's President & CEO, Nick Leschly, currently has an approval rating of 79%. bluebird bio's primary competitors are Sangamo, Ember Therapeutics & Recombinetics.

Website

bluebirdbio.com

Frequently Asked Questions about bluebird bio

  1. When was bluebird bio founded?

    bluebird bio was founded in 1992

  2. Who is bluebird bio's CEO?

    bluebird bio's CEO is Nick Leschly

  3. How much revenue does bluebird bio generate?

    bluebird bio generates $44.7M in revenue

  4. How much funding does bluebird bio have?

    bluebird bio has historically raised $275.9M in funding

  1. Where is bluebird bio's headquarters?

    bluebird bio's headquarters is in Cambridge Massachusetts, USA

  2. How many employees does bluebird bio have?

    bluebird bio has 764 employees

  3. What sector does bluebird bio operate in?

    bluebird bio is in Biotechnology

  4. Who are bluebird bio's competitors?

    bluebird bio's top competitors are Sangamo, Ember Therapeutics, Recombinetics
Stay up-to-date with the latest news on bluebird bio